REZOLUTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.99 USD | +4.91% |
|
-9.67% | +201.26% |
| Apr. 18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
| Mar. 06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| REZOLUTE, INC. | Bio Therapeutic Drugs | +4.91% | -9.67% | +201.26% | +44.44% | -66.59% | 120M | - | - | - |
Technical Rankings Surperformance
- Stock Market
- Equities
- RZLT Stock
- Charts Rezolute, Inc.
- Comparison Chart
